Tech Mahindra Clinical Document Studio powered by Kitsa
Tech Mahindra · Intelligence & Research
Certification per AWS Marketplace.
Evidence tier Source Confirmed · 4 captures on record
What the publisher says
As described on AWS Marketplace.
**Overview:**
Tech Mahindra Clinical Document Studio powered by Kitsa is an enterprise-grade AI platform designed to transform clinical trial protocol and regulatory document development for Sponsors, CROs, and biotech companies. This joint offering combines Tech Mahindra’s life sciences transformation expertise and AWS-native deployment capabilities with Kitsa’s AI-powered Protocol Development Studio purpose-built for structured clinical authoring. The platform supports intelligent authoring, benchmarking, validation, and collaboration across the full spectrum of regulatory documentation.
Show the rest of the publisher’s description (24 more lines)
**Comprehensive Regulatory Coverage:**
- Clinical Trial Protocols (Phases I–IV)
- Investigator’s Brochure (IB)
- Informed Consent Forms (ICF)
- Clinical Study Reports (CSR)
- Statistical Analysis Plans (SAP)
- IND / NDA / BLA modules (CTD-aligned structure)
- Global regulatory submission packages (FDA, EMA, MHRA, CDSCO and others)
**Built on AWS for Enterprise-Grade Performance:**
- Amazon EKS for scalable orchestration
- Amazon EC2 for AI workloads
- Amazon RDS and Amazon S3 for secure document storage
- Enterprise-grade encryption, identity, and audit logging Ensures regulatory-grade compliance, scalability, and secure collaboration.
**Key Features:**
- Intelligent Protocol Authoring – AI-guided drafting of objectives, endpoints, eligibility criteria, and statistical frameworks.
- Benchmarking & Disease Intelligence – Compare protocol parameters against historical trials to optimize feasibility and design.
- Regulatory-Ready Documentation – Generate structured content aligned to IND/NDA/CTA submission requirements.
- Collaborative Workflow Engine – Multi-user authoring, review, and version control.
**Benefits:**
- Up to 40% reduction in protocol development timelines
- Improved first-pass regulatory quality
- Standardization across clinical programs
- Secure, scalable AWS-native infrastructure
- Future-ready AI-enabled regulatory automation
Highlights
Highlighted by the publisher on AWS Marketplace.
• AI-assisted protocol authoring aligned to ICH E6 guidelines • Disease intelligence benchmarking across historical trials • Structured design validation to reduce amendments • Built-in collaboration workflows and audit trails • Configurable sponsor-aligned template
Agent build and provenance
See the full provenance
The layer-by-layer build, the evidence behind each claim, the risk basis and the cross-marketplace links are open to any account. Some rows are disclosed, some the source leaves Unknown; a free account shows you which.
Compliance
- FedRAMPConfirmedNot listed90%, registry-checkedNo FedRAMP Marketplace entry matched this vendor's domain, checked 2026-08-27registry recordas observed 2026-08-27
Confirmed means matched to a public authoritative registry. Claimed means the vendor or its listing states it, not yet cross-checked. A framework not shown was not found in any source we hold, which is not evidence against it. Not listed means a scoped registry check found no match for this vendor's domain: a No is a scoped registry check, not a compliance judgment. Confidence bands: 95% domain-verified, 90% registry-checked, 80% self-attested, 70% weak signal. Self-attested items marked “vendor's site” are gathered from the vendor's own website and are not verified by us.
Vendor
External enrichment · as of 2026-08-29
Sources
Linked repositories
Unknown means this listing does not publish a repository. It is not a statement that the code is closed, and a linked repository is not a claim that the publisher wrote it: the registry computes that relationship privately and does not publish it.
Evidence risk is the share of the build you cannot see before you deploy, not a security rating. Sign in to see the layer-by-layer basis for this band.